Pharmaceuticals

Aspire Biopharma

Aspire Biopharma Reports Q3 2025 Business Update and Drug Development Progress

Aspire Biopharma released FY2025 9 Months Earnings on November 14 (EST), actual revenue USD 1.941 K, actual EPS USD -0.4982

Aspire Biopharma released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 1.941 K, actual EPS USD -0.0373

Aspire Biopharma Holdings Inc. Reports Q3 2025 Net Income and Signs Non-Compete Agreements

Aspire Biopharma Discusses Strategic Plans for Sublingual High-Dose Aspirin at CPHI Trade Show

Aspire Biopharma Submits Patent Application for New Sublingual Drug Delivery Platform

Aspire Biopharma to Present Latest Advancements in Sublingual Drug Delivery at Noble Capital Markets

Aspire Biopharma to Submit New Drug Application for Sublingual Aspirin in Late 2025

Aspire Biopharma released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0, actual EPS USD -0.0401

Aspire Biopharma released FY2025 Semi-Annual Earnings on August 13, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.4101

Aspire Biopharma to debut new supplement BUZZ BOMB at FITCON and Fit Expo

Aspire Biopharma Completes Phase 1 Trial of Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma moves headquarters to Florida

Aspire Biopharma showcases sublingual drug delivery technology

Aspire Biopharma Holdings Inc. Names Michael Howe as New CEO

Aspire Biopharma Director Buys Company Shares

Aspire Biopharma to launch BUZZ BOMB™ in Q3 2025

Aspire Biopharma Initiates Clinical Trial for High-Dose Aspirin Formulation

Aspire Biopharma released FY2025 Q1 earnings on May 14 (EST) with actual revenue of USD 0 and EPS of USD -0.4207

Aspire Biopharma released FY2024 Q4 earnings on May 13 (EST), actual revenue USD 0, actual EPS USD -0.0016

Mega Fortune

Processa Pharmaceuticals

cbdMD

Agape ATP

VYNE Therapeutics

Andersen

Inspirato

Medline Inc.

Creative Global Tech

GCI LIBERTY INC COM USD0.01 SER C SUBS RTS 17/12/2025

Eli Lilly

Roche

ROCHE HOLDINGS AG

Astrazeneca

NOVARTIS AG

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Daiichi Sankyo

Otsuka Pharmaceutical

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap